Abstract
Although the occurrence of tumour deposits (TDs) without metastatic lymph nodes (mLNs) is classified as "N1c" in the 8th TNM staging system for colorectal cancer (CRC), the prognostic significance of the TD count is still controversial. A total of 39,155 CRC patients were collected from the Surveillance, Epidemiology, and End Results (SEER) database. The results showed that TD count was an important prognostic factor and that the number of TDs was negatively correlated with the prognosis of CRC patients. We found that the prognostic value of one TD is equivalent to that of two mLNs based on the comparison of CSS rates. Accordingly, we proposed a novel N staging system by integrating the TD count into the N category with the ratio of TDs to mLNs being 1:2. There were no prognostic differences in patients with or without TDs in each novel N category. Weighing one TD as two mLNs in this novel TNM staging system is superior to the "N1c" classification in the 8th TNM staging system in evaluating the prognosis of CRC patients.
Introduction
The TNM (Tumor, Node, Metastasis) staging system is the cornerstone of oncology, guiding treatment decisions and predicting patient outcomes. In colorectal cancer (CRC), "Tumor Deposits" (TDs)—isolated cancer nodules in the peritumoral fat—have historically been difficult to classify. The current 8th edition of the TNM system assigns a "N1c" stage to patients with TDs but no metastatic lymph nodes (mLNs). However, this approach fails to account for the cumulative prognostic impact when both mLNs and TDs are present, and it overlooks the specific count of TDs. This study investigates whether the number of TDs should be integrated more formally into the N-category to improve prognostic accuracy.
Methods
This study utilized a massive cohort of 39,155 CRC patients from the SEER (Surveillance, Epidemiology, and End Results) database diagnosed between 2010 and 2014. Researchers excluded patients who received preoperative chemoradiotherapy to ensure accurate nodal and deposit counts. Statistical analysis involved $\chi^2$ tests for baseline characteristics and Kaplan-Meier modeling for Cancer-Specific Survival (CSS). To determine the optimal weighting for TDs, the team compared survival curves for various TD-to-mLN ratios (1:1, 1:2, 1:3, and 1:4) to identify where prognostic curves overlapped.
Key Results
The presence of TDs was strongly associated with aggressive disease markers, including deeper tumor invasion (higher T-stage) and distant metastasis (M1). The survival analysis demonstrated a clear, significant difference in outcomes between TD-positive and TD-negative patients across various subgroups.
A critical finding was the dose-response relationship between the number of TDs and patient survival. As the count of individual deposits increased, the cancer-specific survival rate dropped significantly, demonstrating that TDs are not just binary markers but have a cumulative effect on prognosis.
The researchers identified a "golden ratio" of 1:2, where the prognostic weight of one TD is equivalent to two mLNs. Based on this, they proposed a novel N staging system (nN) where the total nodal score is calculated as: $$\text{Total Score} = (\text{Number of mLNs}) + (2 \times \text{Number of TDs})$$
Validation of this system showed no significant survival differences between patients with or without TDs within the same novel N category, suggesting the 1:2 weighting accurately reflects biological risk. This weighted system proved superior to the current 8th edition TNM staging in evaluating prognosis.
Discussion and Limitations
Integrating the TD count into a weighted N-stage provides a more precise prognostic tool than the current "N1c" classification. While this study is powered by a large dataset, its retrospective nature means it cannot account for all clinical variations. Furthermore, the biological reason why TDs carry twice the prognostic weight of lymph nodes remains a mystery. Future research should investigate the molecular characteristics of these deposits to understand their aggressive nature.
Before clinical adoption, this "nN" system requires validation in prospective trials and review by international staging committees. However, the evidence strongly suggests that when it comes to colorectal cancer staging, every tumor deposit counts—and they count double.
Summary updated